Drugs

Papers
(The H4-Index of Drugs is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression417
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”395
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments296
Bimekizumab for the Treatment of Psoriasis282
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations218
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences190
Targeting DNA Damage Response Deficiency in Thoracic Cancers169
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema161
Teclistamab: First Approval136
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments135
Spesolimab for the Treatment of Generalized Pustular Psoriasis117
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using113
Aprocitentan: First Approval107
Eftrenonacog Alfa: A Review in Haemophilia B107
Vorasidenib: First Approval105
New Therapies on the Horizon for Primary Biliary Cholangitis103
Epcoritamab: First Approval100
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure98
Finerenone: First Approval96
Upacicalcet: First Approval94
Lenacapavir: First Approval93
Dasiglucagon: First Approval92
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine92
Cosibelimab: First Approval91
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer89
Drugs in Development to Manage Acute Pain88
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies87
Dostarlimab: First Approval86
Atogepant: First Approval84
Androgenetic Alopecia: Therapy Update84
Olipudase Alfa: First Approval84
Repotrectinib: First Approval83
Mosunetuzumab: First Approval82
Danicopan: First Approval82
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?78
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia78
Olverembatinib: First Approval76
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification76
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis75
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection75
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids73
Cancer Pain Treatment Strategies in Patients with Cancer72
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?72
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections70
Correction to: Prevention and Treatment of Monkeypox69
Dorzagliatin: First Approval69
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes69
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology69
Correction to: Tapinarof Cream 1%: First Approval68
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough67
Pozelimab: First Approval66
The Place of Cannabinoids in the Treatment of Gynecological Pain66
Sunvozertinib: First Approval66
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer66
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A66
Tovorafenib: First Approval64
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned64
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis63
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab62
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options62
Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis62
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study61
Gepirone Extended-Release: First Approval61
0.077594041824341